Varenicline

A 13-week randomized trial of 384 patients with moderate to severe alcohol use disorder found that combining varenicline and bupropion produced approximately twice the effect of currently available medications.

• Grandpharma's innovative ophthalmic drug GPN01768 has been approved by Macao's Drug Regulatory Authority for treating Demodex blepharitis, marking a significant milestone for the company's ophthalmology portfolio. • The drug is the first and only FDA-approved treatment for Demodex blepharitis, generating approximately $180 million in U.S. revenue in 2024 with strong quarterly growth momentum. • This approval establishes a foundation for future regulatory submissions in the Greater Bay Area and mainland China, where over 40 million patients suffer from Demodex blepharitis with no currently marketed treatments. • Grandpharma has exclusive rights for GPN01768 development and commercialization in Greater China through a strategic partnership with Tarsus Pharmaceuticals.

A groundbreaking clinical trial reveals varenicline combined with remote behavioral counseling achieved 51% vaping abstinence rates in youth compared to 14% with placebo during the final four weeks of treatment.

Nearly half of young adults successfully quit vaping after three months using a combination of phone-based coaching, health apps, and nicotine replacement therapy, according to new research published in the American Journal of Preventive Medicine.

University of Leicester researchers conducted the first genome-wide study revealing genetic variations affect varenicline's effectiveness in smoking cessation, offering new insights into personalized treatment approaches.